YWYiyi Wang

Yiyi Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yiyi Wang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Arthralgia and Ultrasound Characteristics of Subclinical Psoriatic Arthritis: A Cross‐Sectional Study Based on the SPAWCH Cohort

    by Xiya Peng, Yiyi Wang, Yue Xiao, Hongli Wang, Kun Zhan, Baiq Nickte Annizha Khalik, Jingya Gao, Yi Teng, Hongxiang Hu, Dengmei Xia, et al.

    As a critical stage before psoriatic arthritis (PsA) onset, subclinical PsA provides an opportunity window for early diagnosis and intervention. This study aimed to describe the clinical and ultrasound characteristics of patients fulfilling the EULAR definition of subclinical PsA, and to explore the heterogeneity of arthralgia within this population. Patients fulfilling the EULAR definition of subclinical PsA, characterized by arthralgia and/or ultrasound evidence of synovial/entheseal inflammation without clinical synovitis, were enrolled in the Subclinical Psoriatic Arthritis Cohort of West China Hospital (SPAWCH) Cohort from January 2019 to December 2024. We collected clinical information, arthralgia features, and ultrasound findings, conducting a cross‐sectional analysis. Overall, 306 patients were included in the analysis. Among them, 84 (27.5%) had both arthralgia and ultrasound abnormalities (Group AU), 203 (66.3%) had isolated ultrasound abnormalities (Group IU), and 19 (6.2%) had isolated arthralgia (Group IA). Compared with the Group IU, patients in the Group AU were older (49.3 ± 13.7 vs. 43.5 ± 13.2 years, p = 0.001) and had a longer duration of psoriasis (17.7 ± 12.3 vs. 14.1 ± 9.8 years, p = 0.020). Additionally, the two main arthralgia types were activity‐related (60, 58.3%) and rest‐related (25, 24.3%). Rest‐related arthralgia was associated with prolonged arthralgia duration ( p = 0.041), higher morning stiffness incidence ( p = 0.031), and more prominent inflammatory characteristics ( p = 0.001) compared to activity‐related cases. In this study, ultrasound abnormalities emerged as the dominant feature in patients meeting the EULAR definition of subclinical PsA. Notably, the coexistence of arthralgia and ultrasound abnormalities was associated with a longer duration of psoriasis. While activity‐related arthralgia was the most prevalent type, rest‐related arthralgia.

  • Open Access

    Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort

    by Yiyi Wang, Jingya Gao, Furong Li, Luyuan Li, Yue Xiao, Hongxiang Hu, Xiya Peng, Min Yang, Dan Hao, Wei Yan, et al.

    Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain limited. This study aimed to compare the real‐world effectiveness and safety of ADA, SEC, and UPA in PsA patients. We conducted a prospective cohort study using data from the PARWCH database. PsA patients treated with ADA, SEC, or UPA were included and followed at baseline, Week 4, Week 12, and Week 24. Skin responses were evaluated using PASI75/90. Joint outcomes—including peripheral and axial arthritis—were assessed with ACR, PsARC, and ASAS criteria. Patient‐reported pain, disease activity, and HAQ scores were also recorded. Adverse events (AEs) were monitored throughout treatment. MMRM and GLMM were used to analyze continuous and binary outcomes, respectively. A total of 187 PsA patients were included (SEC: 78; ADA: 66; UPA: 43). All three agents demonstrated comparable effectiveness in improving peripheral joint symptoms (ACR20: SEC vs. ADA, Coef = −0.29, p = 0.62; UPA vs. ADA, Coef = −0.29, p = 0.66) and axial involvement (ASAS20: SEC vs. ADA, Coef = −0.04, p = 0.81; UPA vs. ADA, Coef = −1.05, p = 0.23). UPA and SEC showed significantly greater effectiveness than ADA in improving skin lesions (PASI90: SEC vs. ADA, Coef = 1.84, p = 0.006; UPA vs. ADA, Coef = 1.53, p = 0.04). However, ADA was more effective in relieving pain compared to both UPA (Coef = 2.43, p < 0.001) and SEC (Coef = 1.21, p = 0.02). Over 24 weeks, 85 AEs were reported by 48 patients, with fatigue, rash, upper respiratory tract infection, and pruritus being the most common. No serious AEs occurred. In conclusion, UPA and SEC demonstrated balanced effectiveness across skin and joint domains, while ADA offered superior pain relief. These findings support personalized treatment strategies tailored to the clinical features of PsA patients.


  • Single-Cell Transcriptome Analysis Reveals Interaction between CCL19+ Inflammatory Keratinocytes and CCR7+ Dendritic Cells and B Cells in Pemphigus

    by Yiyi Wang, Shan Zhao, Xiwen Zhang, Dengmei Xia, Yue Xiao, Xingli Zhou, Tongying Zhan, Xuyang Xia, Yang Shu, Heng Xu, et al.


  • Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab

    by Xiwen Zhang, Yue Xiao, Xiaohong Li, Jinqiu Wang, Xingli Zhou, Yiyi Wang, Yuxi Zhou, Mi Wang, Wei Li

    The therapeutic strategy for the treatment of pemphigus vulgaris (PV) still needs optimization because of the multiple deficiencies of glucocorticoid and rituximab. Ofatumumab, another CD20 monoclonal antibody administrated subcutaneously, provides a possible alternative option. In this study, three patients experienced PV relapse after clinical remission induced by rituximab. With written informed consent, they received an ofatumumab (20 mg) subcutaneous injection twice (2 weeks apart) in combination with a prednisone dose adjusted according to their weight and disease severity. Over the 24‐week observation, two of three patients achieved lesion clear‐up under prednisone (0.2 mg/kg per day), and the other patient's pemphigus disease area index dropped from 39 to 3 with prednisone (15 mg/day). The anti‐desmoglein antibody levels and CD19 + B cell counts declined compared to those at baseline. No severe adverse events were observed within the 24‐week follow‐up. In summary, we propose a protocol of ofatumumab for patients with refractory PV and report positive treatment outcomes of three patients who received this regimen.


  • Open Access

    The Characteristics of COVID‐19 Symptoms and Skin Manifestations among Nonhospitalized COVID‐19 Patients with Psoriasis during the Omicron Pandemic in China: A Single‐Center Survey‐Based Study

    by Yue Xiao, Xiwen Zhang, Xun Feng, Jingya Gao, Furong Li, Wenyao Mi, Mingqi Wang, Yuanxia Gu, Yiyi Wang, Wen Wang, et al.

    Background. The global impact of coronavirus 2019 (COVID‐19) has raised concerns about the management of psoriasis patients, especially among those using biologics. Methods. We conducted a survey‐based research among Omicron‐infected (confirmed, probable, and suspected ones) psoriasis patients in the department of dermatology, West China Hospital, Sichuan University, from January 9th to January 22nd, 2023. We collected demographic and clinical information (psoriasis‐ and COVID‐19‐related) and conducted statistics analysis. Results. Of the 240 patients enrolled, they were classified by the psoriatic treatment, as biologics (n = 138), nonbiological systematic treatment (n = 52), and topical treatment or without pharmacological treatment (n = 50). This study showed the characteristics of Omicron‐related symptoms and cutaneous signs in patients. We observed that patients who received topical treatment or without pharmacological treatment had a lower risk of presenting with COVID‐19 symptoms in the fully adjusted logistic model (OR = 0.40, 95% CI: 0.18–0.90, and P = 0.025). Moreover, in the model for skin manifestations, nonbiological systematic treatment (OR = 2.15, 95% CI: 1.08–4.27, and P = 0.029) and high BMI (OR = 1.10, 95% CI: 1.00–1.20, and P = 0.042) were correlative factors. Conclusions. Our data suggested that differential psoriatic treatment might be a correlative factor in developing symptomatic or asymptomatic Omicron infection and presenting cutaneous signs.

  • Open Access

    Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study

    by Gaojie Li, Yuanxia Gu, Qin Zou, Yiyi Wang, Yue Xiao, Dengmei Xia, Tongying Zhan, Xingli Zhou, Qian Wang, Wei Yan, et al.

    Introduction A growing number of biologics have recently been approved in China for psoriasis treatment, and some of these are eligible for Chinese medical insurance, resulting in a significant increase in the number of patients receiving these biologics. Nevertheless, real-world data on the efficacy and safety of biologics for treating moderate-to-severe plaque psoriasis in Chinese patients are limited, and relevant pharmacoeconomic studies are lacking. Therefore, we performed a prospective, single-center study to evaluate the efficacy and safety of adalimumab (ADA) and secukinumab (SEC) in real-world practice. A cost-effectiveness analysis (CEA) was also conducted. Methods Participants were enrolled between January 2019 and December 2020 at the West China Hospital, Sichuan University. Baseline and follow-up assessments were conducted, and an appropriate statistical analysis was performed. Results A total of 183 patients were included. At week 12, the number of patients achieving a psoriasis area and severity index reduction of 75% (PASI 75) with SEC treatment was higher than that with ADA and methotrexate (MTX) (SEC versus ADA versus MTX, 90.59% versus 58.70% versus 17.14%, respectively). Adverse events (AEs) were reported in 44.83% and 56.36% of patients in the SEC and ADA groups, respectively. The cost-effectiveness ratio in the SEC group was 46,311.83 Chinese yuan(CNY), compared with 17,580.92 CNY in the ADA group. Conclusion In real-world practice, SEC and ADA are effective and safe for moderate-to-severe plaque psoriasis treatment in Chinese patients. On the basis of drug prices during our study period without considering access to health insurance, ADA was more cost-effective in real-world practice. Plain Language Summary Adalimumab and secukinumab are two monoclonal antibodies used for the treatment of psoriasis, which target different cytokines in the pathogenesis. A growing number of biologics have recently been approved in China for psoriasis treatment including adalimumab and secukinumab, which are eligible for Chinese medical insurance, resulting in a significant increase in the number of patients receiving these biologics. With the purpose of evaluating its efficacy and safety in the real world, we registered the data of eligible patients in West China Hospital, Sichuan University over the past two years and conducted statistical analysis. In order to provide different therapeutic strategies for patients based on case-specific needs and access to financial resources, we performed pharmacoeconomic analyses to evaluate the cost-effectiveness of the two drugs. Our study demonstrated that adalimumab and secukinumab were effective and safe for moderate-to-severe plaque psoriasis in Chinese patients in the real-world practice. Based on drug prices during our study period and without taking into consideration access to health insurance, ADA was more cost-effective in real-world practice.


  • Open Access

    The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China

    by Yue Xiao, Hui Chen, Qin Zou, Yiyi Wang, Yuanxia Gu, Jinqiu Wang, Wei Yan, Wei Li

    Introduction The tuberculosis (TB) positive conversion rate among psoriasis patients who received biologics has been reported worldwide, particularly in regions with low TB risk. Nonetheless, the TB-related safety of biologics such as adalimumab and secukinumab remains elusive in areas with high TB risk. According to the World Tuberculosis Report 2021, China is the country with the second highest TB burden, but data on TB conversion are also limited. Thus, we performed a retrospective, single-center study to profile the TB infection status conversion ratio among psoriasis patients treated with adalimumab and secukinumab in China. Methods Patients were enrolled between April 2019 and February 2021 from West China Hospital, Sichuan University. Baseline and relevant clinical information were summarized, and proper statistical analysis was used under different conditions. Results Five (5.43%) patients suffered TB conversion in the adalimumab group, two of whom developed active TB within the first 6 months. In the secukinumab group, four (5.26%) patients had TB positive conversion with no reports of active TB. Conclusion Our data show a relatively high rate of TB conversion among these psoriasis patients after mean treatment duration of 17.13 months. We recommend that, in patients who receive adalimumab, TB be reevaluated after the first 3 months and then monitored semiannually for the next 2 years. For patients treated with secukinumab, annual examination is sufficient.


  • Open Access

    Development of a Predictive Model for Screening Patients with Psoriasis at Increased Risk of Psoriatic Arthritis

    by Yiyi Wang, Lingyan Zhang, Min Yang, Yanze Cao, Mingxin Zheng, Yuanxia Gu, Hongxiang Hu, Hui Chen, Min Zhang, Jingyi Li, et al.

    Introduction This study aimed to develop a predictive model based on ultrasound variables which can be used to screen patients with psoriasis who are prone to progress to psoriatic arthritis (PsA) in clinical practice. Methods This is a cross-sectional study conducted in a single center from October 2018 to November 2020. All subjects (non-PsA group, PsA group, and control group) underwent an ultrasound examination and their ultrasound abnormalities were recorded. On the basis of statistical analysis and clinical experts’ advice, several variables were selected for modelling. We used logistic regression to establish the prediction model. To assess the discrimination and accuracy of this model, internal validation and external validation were performed. Results A total of 852 patients with psoriasis but without PsA, 261 patients with PsA, and 86 healthy volunteers were included. Ultimately, the predictive model consisted of six variables, namely hand joint power Doppler (PD) signals (grade 0: OR 2.94, 95% CI 1.94–4.47; grade ≥ 1: OR 109.30, 95% CI 14.35–832.27; P < 0.001), wrist joint synovial thickening (grade 1: OR 1.29, 95% CI 0.69–2.43; grade 2: OR 4.30, 95% CI 1.92–9.65; grade 3: OR 11.05, 95% CI 1.01–120.64; P = 0.001), knee joint PD signals (grade 0: OR 1.01, 95% CI 0.56–1.80; grade ≥ 1: OR 14.77, 95% CI 3.99–54.69; P < 0.001), toe joint PD signals (grade 0: OR 1.18, 95% CI 0.78–1.79; grade ≥ 1: OR 5.74, 95% CI 2.84–11.63; P < 0.001), quadriceps tendon and patellar tendon enthesitis (OR 1.95, 95% CI 1.36–2.78, P < 0.001), Achilles tendon and plantar aponeurosis enthesitis (OR 1.63, 95% CI 1.14–2.32, P = 0.007). C-index for the predictive model was 0.80 (95% CI 0.76–0.83). After bootstrapping validation (1000 times), it was confirmed to be 0.79. The external validation showed the accuracy of the predictive model is 0.87 (95% CI 0.69–0.95). Conclusion This study succeeded in developing a predictive model with a high degree of accuracy to predict the risk of PsA in patients with psoriasis.